Opportunities and challenges using artificial intelligence in ADME/Tox
- PMID: 31000801
- PMCID: PMC6594826
- DOI: 10.1038/s41563-019-0332-5
Opportunities and challenges using artificial intelligence in ADME/Tox
Abstract
A recent conference organized a panel of scientists representing small and big pharma companies, who work at the interface of machine learning (ML) and absorption, distribution, metabolism, excretion, and toxicology (ADME/Tox). With the recent rebirth of AI related to pharma, it is timely to present this collaborative commentary to capture the diverging opinions on the past, present and future role of AI for ADME/Tox and how it can be applied in newer areas such as nanomaterials.
References
-
- Gupta RR et al. Drug Metab Dispos 38, 2083–2090 (2010). - PubMed
-
- Ekins S, Honeycutt JD& Metz JT Drug Discov Today 15, 451–460 (2010). - PubMed
-
- Page KM Mol Pharm 13, 609–620 (2016). - PubMed
-
- Webborn PJ Future Med Chem 6, 1233–1235 (2014). - PubMed
-
- Zientek M et al. Chem Res Toxicol 23, 664–676 (2010). - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
